

## DAFTAR PUSTAKA

- Armitage, J.O., 2005, Staging Non-Hodgkin Lymphoma, *CA. Cancer J. Clin.*, 55, 368–376.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A., 2018, Global Cancer Statistics 2018 : Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, *CA : A Cancer Journal for Clinicians*, Volume 68, Issue 6 <https://doi.org/10.3322/caac.21492>.
- Campuzano-Zuluaga, G., Pimentel, A., Chapman-Fredricks, J.R., and Ramos, J., 2014, Differential CD30 expression in adult T-cell leukemia-lymphoma subtypes, *Retrovirology*, 11, P129.
- Cheson, B.D., 2015, Staging and response assessment in lymphomas: the new Lugano classification., *Chinese Clin. Oncol.*, 4, 5.
- Cioroianu, A.I., Stinga, P.I., Sticlaru, L., Cioplea, M.D., Nichita, L., Popp, C., and Staniceanu, F., 2019, Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis, *Anal. Cell. Pathol.*, 2019, 1–9 [doi:10.1155/2019/8586354](https://doi.org/10.1155/2019/8586354).
- Dotan, E., Aggarwal, C., and Smith, M.R., 2010, Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma., *P T*, 35, 148–57.
- Goldstein, N.S., Hewitt, S.M., Taylor, C.R., Yaziji, H., and Hicks, D.G., 2007, Recommendations for Improved Standardization of Immunohistochemistry, *Appl. Immunohistochem. Mol. Morphol.*, 15, 124–133 [doi:10.1097/pai.0b013e31804c7283](https://doi.org/10.1097/pai.0b013e31804c7283).
- Gong, Q.X., Lu, T.X., Liu, C., Wang, Z., Liang, J.H., Xu, W., et al., 2015, Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: A retrospective study of 232 cases, *Int. J. Clin. Exp. Pathol.*, 8, 15825–15835.
- Gong, Q.-X., Wang, Z., Liu, C., Li, X., Lu, T.-X., Liang, J.-H., et al., 2018, CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma, *J. Clin. Pathol.*, 71, 795–801.
- Gown, A.M., 2016, Diagnostic Immunohistochemistry: What Can Go Wrong and How to Prevent It, *Arch. Pathol. Lab. Med.*, 140, 893–898 [doi:10.5858/arpa.2016-0119-ra](https://doi.org/10.5858/arpa.2016-0119-ra).

- Gurbaxani, S., Anastasi, J., and Hyjek, E., 2009, Diffuse large B-cell lymphoma--more than a diffuse collection of large B cells: an entity in search of a meaningful classification., *Arch. Pathol. Lab. Med.*, 133, 1121–34.
- Hao, X., Wei, X., Huang, F., Wei, Y., Zeng, H., Xu, L., et al., 2015, The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma, *PLoS One*, 10, e0126615.
- Hoppe, R.T., Mauch, P.M., Armitage, J.O., Diehl, V., and Weiss, M., 2007, Hodgkin Lymphoma, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.
- Horesh, N. and Horowitz, N.A., 2014, Does Gender Matter in Non-Hodgkin Lymphoma? Differences in Epidemiology, Clinical Behavior, and Therapy, *Rambam Maimonides Med. J.*, 5, e0038.
- Horvat, M., Zadnik, V., Južnič Šetina, T., Boltežar, L., Pahole Goličnik, J., Novaković, S., and Jezeršek Novaković, B., 2018, Diffuse large B-cell lymphoma: 10½years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone, *Oncol. Lett.*, 15, 3602–3609.
- Hu, S., Xu-Monette, Z.Y., Balasubramanyam, A., Manyam, G.C., Visco, C., Tzankov, A., et al., 2013, CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study, *Blood*, 121, 2715–2724.
- Indonesia Source : Globocan 2018, 2019, The Global Cancer Observatory.
- Jacobsen, E.D., Sharman, J.P., Oki, Y., Advani, R.H., Winter, J.N., Bello, C.M., et al., 2015, Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression, *Blood*, 125, 1394–1402.
- Jaffe, E., Harris, N.L., Vardiman, J., Campo, E., Arber, D., 2011, Hematopathology 9th ed, Philadelphia, PA : Saunders, Elsevier.
- Katz, J., Janik, J.E., and Younes, A., 2011, Brentuximab Vedotin (SGN-35), *Clin. Cancer Res.*, 17, 6428–6436.
- Kim, S.-W., Roh, J., and Park, C.-S., 2016, Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips, *J. Pathol. Transl. Med.*, 50, 411–418 doi:10.4132/jptm.2016.08.08.

- Koens, L., van de Ven, P.M., Hijmering, N.J., Kersten, M.J., Diepstra, A., Chamuleau, M., and de Jong, D., 2018, Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment, *Histopathology*, 73, 473–482.
- Li, S., Young, K.H., and Medeiros, L.J., 2018, Diffuse large B-cell lymphoma, *Pathology*, 50, 74–87.
- Menon, M.P., Pittaluga, S., and Jaffe, E.S., 2012, The Histological and Biological Spectrum of Diffuse Large B-Cell Lymphoma in the World Health Organization Classification, *Cancer J.*, 18, 411–420.
- Mori, M., Manuelli, C., Pimpinelli, N., Mavilia, C., Maggi, E., Santucci, M., et al., 1999, CD30-CD30 Ligand Interaction in Primary Cutaneous CD30+T-Cell Lymphomas: A Clue to the Pathophysiology of Clinical Regression, *Blood*, 94, 3077–3083.
- Mulder, T.A., Wahlin, B.E., Osterborg, A., Palma, M., 2019, Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin : From Biology to Clinical Application, *Cancers*, 11, 915 doi:10.3390/cancers11070915.
- Quintanilla-Martinez, L., 2017, The 2016 updated WHO classification of lymphoid neoplasias, *Hematol. Oncol.*, 35, 37–45.
- Reksodiputro, A.H., 2015, Multicentre Epidemiology and Survival Study of B Cell Non Hodgkin Lymphoma Patients In Indonesia, *J. Blood Disord. Transfus.*, 06, 2–6.
- Said, J.W., 2013, Aggressive B-cell lymphomas: how many categories do we need?, *Mod. Pathol.*, 26, S42–S56.
- Shi, S.-R., Cote, R.J., and Taylor, C.R., 1997, Antigen Retrieval Immunohistochemistry: Past, Present, and Future, *J. Histochem. Cytochem.*, 45, 327–343 doi:10.1177/002215549704500301.
- Slack, G.W., Steidl, C., Sehn, L.H., and Gascoyne, R.D., 2014, CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia, *Br. J. Haematol.*, 167, 608–617.
- Smith, A., Crouch, S., Howell, D., Burton, C., Patmore, R., and Roman, E., 2015, Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma, *Cancer Epidemiol.*, 39, 1103–1112.

- Wang, X.J., Seegmiller, A.C., Reddy, N.M., and Li, S., 2016, CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma, *Eur. J. Haematol.*, 97, 39–47.
- Wasik, M.A., Jimenez, G.S., and Weisenburger, D.D., 2013, Targeting CD30 in malignant tissues: Challenges in detection and clinical applications, *Pathobiology*, 80, 252–258.
- van der Weyden, C.A., Pileri, S.A., Feldman, A.L., Whisstock, J., and Prince, H.M., 2017, Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions, *Blood Cancer J.*, 7, e603 doi:10.1038/bcj.2017.85.
- Xu, J., Oki, Y., Saksena, A., Desai, P., Lin, P., Tang, G., et al., 2017, CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma, *Hum. Pathol.*, 60, 160–166.
- Xue, Y., Wang, Q., and He, X., 2015, Case Report Clear cell variant of diffuse large B-cell lymphoma : a case report and review of the literature , *Int J Clin Exp Pathol*, 8(6), 7594-7599.
- Yi, J.H., Kim, S.J., and Kim, W.S., 2017, Brentuximab vedotin: clinical updates and practical guidance, *Blood Res.*, 52, 243.